Why is Glenmark Pharma falling/rising?

As of 21-Jul, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs 2,187.50, which reflects a decrease of Rs 35.55 or 1.6%. The stock has underperformed its sector by 1.28% today and has been on a downward trend for the past two days, accumulating a total loss of 1.76%. Despite this recent decline, the stock has shown strong performance over the longer term, with a 55.36% return over the past year and a remarkable 474.00% increase over the last three years. The company's ability to service debt is strong, evidenced by a low Debt to EBITDA ratio of 1.00 times, and it has reported positive results for the last four consecutive quarters, including a significant growth in PAT. However, the stock's recent performance is tempered by a notable drop in investor participation, with delivery volume falling by 70.26% against the five-day average. In the broader market context, Glenmark's short-term performance has been less favorable compared to the benchmark, with a 1.38% decline over the past week against a minimal drop of 0.06% in the Sensex. While the stock has consistently outperformed the BSE500 over the last three years, the recent underperformance in the short term may be contributing to investor caution. The high institutional holdings at 37.8% indicate that knowledgeable investors are backing the stock, which could provide some stability despite the current price drop. Overall, while Glenmark Pharmaceuticals has demonstrated strong long-term growth and fundamentals, the recent decline in price reflects short-term market dynamics and reduced trading activity.